Minneapolis,
Minnesota
55415
Purpose:
The purpose of this study is to evaluate the effectiveness of two adaptive treatment
strategies (ATSs) for adolescent depression. The ATSs include delivery of an evidence-based
psychotherapy (interpersonal psychotherapy for depressed adolescents, IPT-A), systematic
symptom monitoring, and an empirically-derived algorithm that specifies whether, when, and
how to augment IPT-A. Two hundred depressed adolescents (age 12-18) will be recruited to
participate in a 16-week sequential multiple assignment randomized trial conducted in
outpatient community mental health clinics. Adolescents will be randomized to the IPT-A ATS
condition or the community clinic's usual care (UC). Adolescents in the IPT-A ATS condition
who are insufficient responders will be randomized a second time to the addition of a
selective serotonin reuptake inhibitor (SSRI) or more intensive IPT-A (delivered twice per
week). Research assessments will be administered at baseline and at weeks 4, 8, 12, 16, and
36.
Criteria:
Inclusion Criteria:
- Meet DSM-V criteria for a primary diagnosis of Major Depressive Disorder, Persistent
Depressive Disorder, or Depressive Disorder NEC
- Current significant depressive symptoms (based on Children's Depression Rating Scale -
Revised [CDRS-R] & Beck Depression Inventory-II [BDI-II])
- Current impairment in psychosocial functioning (based on Children's Global Assessment
Scale [CGAS])
Exclusion Criteria:
- Non English-speaking
- Meet DSM-V criteria for bipolar disorder, psychosis, anorexia nervosa, substance use
disorder, autism spectrum disorder, or intellectual disability disorder.
- Adolescents who are actively suicidal with a plan and/or intent who are assessed to
need a higher level of care than outpatient treatment due to safety risk will be
referred for appropriate level of stabilization. Once stabilized, the adolescent can
be re-evaluated for eligibility to participate in the study.
- Currently taking medication for a psychiatric diagnosis other than ADHD
- Females who are pregnant, breastfeeding, or having unprotected sexual intercourse, due
to the possibility of randomization to treatment with an SSRI.